The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Darren PanDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Darren Pan, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Are chimeric antigen receptor (CAR) T-cell therapies effective in the treatment of extramedullary multiple myeloma?
Are CAR T-cell therapies effective in the treatment of extramedullary MM?
Pan discusses the efficacy of CAR T-cell therapies in patients with multiple myeloma with varying degrees of extramedullary involvement; he considers how involvement influences initial responses, progression-free survival, and durability of response. Pan concludes by examining resistance factors to CAR T-cell therapies and highlighting areas that require further investigation in clinical trials.